Genetic Variation in DNA Repair Genes and Prostate Cancer Risk: Results from a Population-based Study

Overview

Journal Cancer Causes Control

Specialties Oncology
Public Health

Date 2009 Nov 11

PMID 19902366

Citations 49

Authors

Ilir Agalliu

Erika M Kwon

Claudia A Salinas

Joseph S Koopmeiners

Elaine A Ostrander

Janet L Stanford

Affiliations

Soon will be listed here.

Abstract

Objective: DNA repair pathways are crucial to prevent accumulation of DNA damage and maintain genomic stability. Alterations of this pathway have been reported in many cancers. An increase in oxidative DNA damage or decrease in DNA repair capacity with aging or due to germline genetic variation may affect prostate cancer risk.

Methods: Pooled data from two population-based studies (1,457 cases and 1,351 controls) were analyzed to examine associations between 28 single-nucleotide polymorphisms (SNPs) in nine DNA repair genes (APEX1, BRCA2, ERCC2, ERCC4, MGMT, MUTYH, OGG1, XPC, and XRCC1) and prostate cancer risk. We also explored whether associations varied by smoking, by family history or clinical features of prostate cancer.

Results: There were no associations between these SNPs and overall risk of prostate cancer. Risks by genotype also did not vary by smoking or by family history of prostate cancer. Although two SNPs in BRCA2 (rs144848, rs1801406) and two SNPs in ERCC2 (rs1799793, rs13181) showed stronger associations with high Gleason score or advanced-stage tumors when comparing homozygous men carrying the minor versus major allele, results were not statistically significantly different between clinically aggressive and non-aggressive tumors.

Conclusion: Overall, this study found no associations between prostate cancer and the SNPs in DNA repair genes. Given the complexity of this pathway and its crucial role in maintenance of genomic stability, a pathway-based analysis of all 150 genes in DNA repair pathways, as well as exploration of gene-environment interactions may be warranted.

Citing Articles

(CAG) Microsatellite and c.444T>G (p.Asp148Glu) Polymorphisms as Independent Prognostic Biomarkers in Prostate Cancer: Insights from an Argentinian Cohort.

Pascual G, Sabater A, Bizzotto J, Seniuk R, Sanchis P, Ledesma-Bazan S Cancers (Basel). 2024; 16(22).

PMID: 39594771 PMC: 11592882. DOI: 10.3390/cancers16223815.

hOGG1 rs1052133 Polymorphism and Prostate Cancer Risk: A Chinese Case-Control Study and Meta-Analysis.

Xu H, Zhang M, Hao Z, Liang C Med Sci Monit. 2022; 28:e938012.

PMID: 36310366 PMC: 9635216. DOI: 10.12659/MSM.938012.

Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial.

Gong Z, Platek M, Till C, Goodman P, Tangen C, Platz E Front Oncol. 2022; 11:808715.

PMID: 35096612 PMC: 8795906. DOI: 10.3389/fonc.2021.808715.

Association of a common genetic variant (insertion/deletion) in ACE gene with prostate cancer susceptibility in a Tunisian population.

Said R, Jenni R, Boussetta S, Ammous F, Zouari S, Zaghbib S J Clin Lab Anal. 2021; 36(1):e24129.

PMID: 34799866 PMC: 8761439. DOI: 10.1002/jcla.24129.

The rs11615, rs2276466, rs2228000 and rs2228001 polymorphisms increase the cervical cancer risk and aggressiveness in the Bangladeshi population.

Das S, Naher L, Aka T, Aziz M, Shabnaz S, Shahriar M Heliyon. 2021; 7(1):e05919.

PMID: 33490679 PMC: 7809183. DOI: 10.1016/j.heliyon.2021.e05919.

References

Braithwaite E, Wu X, Wang Z . Repair of DNA lesions induced by polycyclic aromatic hydrocarbons in human cell-free extracts: involvement of two excision repair mechanisms in vitro. Carcinogenesis. 1998; 19(7):1239-46. DOI: 10.1093/carcin/19.7.1239. View

Edwards S, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P . Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2002; 72(1):1-12. PMC: 420008. DOI: 10.1086/345310. View

Pierce A, Stark J, Araujo F, Moynahan M, Berwick M, Jasin M . Double-strand breaks and tumorigenesis. Trends Cell Biol. 2001; 11(11):S52-9. DOI: 10.1016/s0962-8924(01)02149-3. View

Ritchey J, Huang W, Chokkalingam A, Gao Y, Deng J, Levine P . Genetic variants of DNA repair genes and prostate cancer: a population-based study. Cancer Epidemiol Biomarkers Prev. 2005; 14(7):1703-9. DOI: 10.1158/1055-9965.EPI-04-0809. View

Kirchhoff T, Kauff N, Mitra N, Nafa K, Huang H, Palmer C . BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res. 2004; 10(9):2918-21. DOI: 10.1158/1078-0432.ccr-03-0604. View

Ostrander E, Udler M . The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev. 2008; 17(8):1843-8. PMC: 2562346. DOI: 10.1158/1055-9965.EPI-08-0556. View

Hirata H, Hinoda Y, Tanaka Y, Okayama N, Suehiro Y, Kawamoto K . Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer. 2007; 43(2):231-7. DOI: 10.1016/j.ejca.2006.11.005. View

Agalliu I, Karlins E, Kwon E, Iwasaki L, Diamond A, Ostrander E . Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer. 2007; 97(6):826-31. PMC: 2360390. DOI: 10.1038/sj.bjc.6603929. View

Breslow N, Day N . Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ. 1980; (32):5-338. View

10.

Cooke M, Evans M, Dizdaroglu M, Lunec J . Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003; 17(10):1195-214. DOI: 10.1096/fj.02-0752rev. View

11.

Stanford J, Wicklund K, McKnight B, Daling J, Brawer M . Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1999; 8(10):881-6. View

12.

Goode E, Ulrich C, Potter J . Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002; 11(12):1513-30. View

13.

Agalliu I, Salinas C, Hansten P, Ostrander E, Stanford J . Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008; 168(3):250-60. PMC: 2585510. DOI: 10.1093/aje/kwn141. View

14.

Hu J, Craig Hall M, Grossman L, Hedayati M, McCULLOUGH D, Lohman K . Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res. 2004; 64(3):1197-201. DOI: 10.1158/0008-5472.can-03-2670. View

15.

Hu J, Mohrenweiser H, Bell D, Leadon S, Miller M . Symposium overview: genetic polymorphisms in DNA repair and cancer risk. Toxicol Appl Pharmacol. 2002; 185(1):64-73. DOI: 10.1006/taap.2002.9518. View

16.

Sunyaev S, Ramensky V, Koch I, Lathe 3rd W, Kondrashov A, Bork P . Prediction of deleterious human alleles. Hum Mol Genet. 2001; 10(6):591-7. DOI: 10.1093/hmg/10.6.591. View

17.

Rybicki B, Conti D, Moreira A, Cicek M, Casey G, Witte J . DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13(1):23-9. DOI: 10.1158/1055-9965.epi-03-0053. View

18.

Chen L, Ambrosone C, Lee J, Sellers T, Pow-Sang J, Park J . Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. J Urol. 2006; 175(1):108-12. DOI: 10.1016/S0022-5347(05)00042-X. View

19.

Sikka S . Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention--a mechanistic approach. Curr Med Chem. 2003; 10(24):2679-92. DOI: 10.2174/0929867033456341. View

20.

Bostwick D, Alexander E, Singh R, Shan A, Qian J, Santella R . Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer. 2000; 89(1):123-34. View